Robin Bhattacherjee, General Manager of Actelion, was re-elected vice-Chair of the EMG; and Mike Sumpter, CEO of Servier Laboratories, was elected Treasurer.
Issues highlighted at the EMG’s twelfth AGM included the impact of NHS reform on European-based companies and European perceptions of the UK as a pharmaceutical market and research base.
The EMG’s 15 member companies are Actelion, Almirall, Bayer, Boehringer Ingelheim, Ferring, Lundbeck, Menarini, Merck Serono, Norgine, Novartis, Novo Nordisk, Roche, Sanofi, Servier and UCB.
Steve Turley (pictured) commented: “We have members ranging from the UK’s biggest pharmaceutical companies, through biotechnology specialists to emerging organisations. Yet we all share common challenges and can benefit from being able to view these through a European-focused lens.”
“How the implementation of the NHS reforms affects European-based companies is a key issue this year,” noted Robin Bhattacherjee.
“Upwards of 60% of the medicines our members have introduced in the last decade have not been subject to a NICE health technology appraisal, so… local decision making in the CCGs about the use of these remains a major focus for EMG.”
Mike Sumpter noted: “Globally the UK is viewed as a tough market where innovative new medicines aren’t adopted as readily as similar economies.
“We want to work closely with our NHS stakeholder partners to demonstrate that the UK and the NHS is worth investing in.”
Lundbeck is based in Denmark, Actelion in Switzerland and Servier in France; all three companies have major UK operations.